ORIGINAL RESEARCH

Efficacy of commercial bacteriophage products against ESKAPE pathogens

About authors

Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia

Correspondence should be addressed: Nikita S. Kuptsov
Malaya Pirogovskaya, 1a, Moscow, 119435; moc.liamg@snvostpuk

About paper

Funding: all study expenses were covered by the funds allocated for the State Assignment on the Development of a personalized approach to the therapy of infections using virulent bacteriophages (Code: Bacteriophage).

Acknowledgements: the authors thank the Center for Precision Genome Editing and Genetic Technologies for Biomedicine, the Federal Research and Clinical Center of Physical-Chemical Medicine of the Federal Medical Biological Agency for their help with bacterial gene sequencing and for subsequent multilocus sequencing typing.

Author contribution: Kuptsov NS — study plan; data acquisition and analysis; manuscript preparation; Kornienko MA — study plan; data analysis; manuscript preparation; Gorodnichev RB, Parfenova TV — data acquisition and analysis; Danilov DI, Malakhova MV — data acquisition; Makarenko GI — sample collection; Shitikov EA — data analysis; manuscript preparation; Ilina EN — manuscript preparation.

Received: 2020-05-06 Accepted: 2020-05-20 Published online: 2020-05-26
|
  1. World Health Organization. Antimicrobial resistance: global report on surveillance 2014. World Heal Organ. 2014: 1–257.
  2. Rice LB. Progress and Challenges in Implementing the Research on ESKAPE Pathogens. Infect Control Hosp Epidemiol. Cambridge University Press (CUP). 2010; 31 (S1): S7–S10.
  3. Zemko VY, Okulich VK, Dzyadzko AM. Monitoring the antibiotic resistance in the intensive care unit of a multidisciplinary hospital. Transplantologiya. The Russian Journal of Transplantation. 2018; 10 (4): 284–97.
  4. Skleenova EYu, Azizov IS, Shek ЕА, Edelstein MV, Kozlov RS, Dekhnich AV. Pseudomonas aeruginosa: the history of one of the most successful nosocomial pathogens in Russian hospitals. Clin Microbiol Antimicrob Chemother. 2018; 3: 164–71.
  5. European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe 2018. Stockholm: ECDC, 2019.
  6. Jennes S, et al. Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury-a case report. Critical Care. 2017; 21 (1).
  7. Breederveld RS. Phage therapy 2.0: where do we stand? The Lancet Infectious Diseases. 2019; 19 (1): 2–3.
  8. Kornienko MA, Ilina EN, Borovskaya AD, Edelstein MV, Sukhorukova MV, Kostrzewa M, et al. Strain differentiation of staphylococcus aureus by means of direct maldi tof mass spectrometry profiling. Biomeditsinskaya Khimiya. 2012; 58 (5): 501–13. Russian.
  9. M100 Performance Standards for Antimicrobial Susceptibility Testing An informational supplement for global application developed through the Clinical and Laboratory Standards Institute consensus process. 29th Edition. January 2019.
  10. Institut Pasteur MLST databases and software. Klebsiella pneumonia: Available from: https://bigsdb.pasteur.fr/klebsiella/ klebsiella.html.
  11. Pubmlst: Public databases for molecular typing and microbial genome diversity. Available from: https://pubmlst.org/databases/.
  12. Diancourt L, et al. Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J Clin Microbiol. 2005; 43 (8): 4178–82.
  13. Jolley KA, Bray JE, Maiden MCJ. Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications. Wellcome open Res. 2018; 3: 124.
  14. Pubmlst: Public databases for molecular typing and microbial genome diversity. Enterococcus faecium. Available from: https:// pubmlst.org/efaecium/.
  15. Harmsen D, et al. Typing of Methicillin-Resistant Staphylococcus aureus in a University Hospital Setting by Using Novel Software for spa Repeat Determination and Database Management. J Clin Microbiol. 2003; 41 (12): 5442–8.
  16. Mazzocco A, et al. Enumeration of bacteriophages using the small drop plaque assay system. Methods Mol Biol. 2009; 501: 81–85.
  17. Lin T-L, et al. Isolation of a bacteriophage and its depolymerase specific for K1 capsule of Klebsiella pneumoniae: implication in typing and treatment. J Infect Dis. 2014; 210 (11): 1734–44.
  18. Cubero M, et al. Hypervirulent Klebsiella pneumoniae clones causing bacteraemia in adults in a teaching hospital in Barcelona, Spain (2007–2013). Clin Microbiol Infect. 2016; 22 (2): 154–60.
  19. Ozkan I, et al. Lytic Activity of Various Phage Cocktails on Multidrug-Resistant Bacteria. Clin Invest Med. 2016; 39 (6): 27504.
  20. Leskinen K, et al. Characterization of vB_SauM-fRuSau02, a twort-like bacteriophage isolated from a therapeutic phage cocktail. Viruses. 2017; 9 (9): Е258.
  21. Dvořáčková M, et al. Antimicrobial effect of commercial phage preparation Stafal® on biofilm and planktonic forms of methicillin-resistant Staphylococcus aureus. Folia Microbiol. 2019; 64 (1): 121–26.
  22. Xia G, et al. Wall teichoic acid-dependent adsorption of staphylococcal siphovirus and myovirus. J Bacteriol. 2011; 193 (5): 4006–9.